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Abstract 
The identification of genes involved in tumor growth is crucial for the development of inventive 
anti-cancer treatments. Here, we have cloned a 17-kDa secretory protein encoded by c19orf10 from 
hepatocellular carcinoma (HCC) serial analysis of gene expression libraries. Gene expression 
analysis indicated that c19orf10 was overexpressed in approximately two-thirds of HCC tissues 
compared with the adjacent non-cancerous liver tissues, and its expression was significantly 
positively correlated with that of alpha-fetoprotein (AFP). Overexpression of c19orf10 enhanced 
cell proliferation of AFP-negative HLE cells, whereas knockdown of c19orf10 inhibited cell 
proliferation of AFP-positive Hep3B and HuH7 cells along with G1 cell cycle arrest. 
Supplementation of recombinant c19orf10 protein in culture media enhanced cell proliferation in 
HLE cells, and this effect was abolished by the addition of antibodies developed against c19orf10. 
Intriguingly, c19orf10 could regulate cell proliferation through the activation of 
Akt/mitogen-activated protein kinase pathways. Taken together, these data suggest that c19orf10 
might be one of the growth factors and potential molecular targets activated in HCC. 
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Introduction 
Hepatocellular carcinoma (HCC) is one of the most common cancers with an estimated worldwide 
incidence of 1,000,000 cases per year 1. Most HCCs develop as a consequence of chronic liver 
disease such as chronic viral hepatitis due to hepatitis C virus (HCV) or hepatitis B virus (HBV) 
infection 2-7. Liver cirrhosis patients with any etiology are considered to be at an extremely high risk 
for HCC 8-10. Indeed, approximately 7% of liver cirrhosis patients with HCV infection develop HCC 
annually 8, 11, and the advancement of reliable HCC screening methods for high-risk patients is 
crucial for the improvement of their overall survival 12. 
Currently, imaging diagnostic techniques such as ultrasonography, computed tomography, 
magnetic resonance image, and angiography are the gold standards for the early detection of HCC 13, 
14. In addition, tumor markers such as alpha-fetoprotein (AFP) and des-gamma carboxyl 
prothrombin (DCP) have been used for the screening of HCC 15-18, although their sensitivity and 
specificity are not sufficiently high. Recently, a gene expression profiling approach shed new light 
on Glypican 3, a heparin-sulfate proteoglycan anchored to the plasma membrane, as a potential 
HCC marker, and its clinical usefulness as a molecular target as well as a tumor marker is presently 
under investigation 19.  
There are several options available for the treatment of HCC, including surgical resection, 
liver transplantation, radio-frequency ablation, transcatheter arterial chemoembolization, and 
chemotherapy, while taking the HCC stage and liver function into consideration. Recently, 
molecular therapy targeting the Raf kinase/vascular endothelial growth factor receptor (VEGFR) 
kinase inhibitor sorafenib improved the survival of patients with advanced HCC 20, 21, emphasizing 
the importance of deciphering the molecular pathogenesis of HCC for the development of effective 
treatment options.  
Here we investigated the gene expression profiles of HCC by serial analysis of gene 
expression (SAGE) to discover a novel gene activated in HCC 22-25. We identified a gene, c19orf10, 
overexpressed in HCC, and determined that the encoded 17-kDa protein (c19orf10) is a secretory 
protein. Murine c19orf10 was originally discovered to encode a cytokine interleukin 
(IL)-25/stroma-derived growth factor (SF20) in 2001 26. The gene c19orf10 was mapped in the H2 
complex region of mouse chromosome 17 between C3 and Ir5, and the hypothetical protein was 
predicted as globular protein 26. However, the subsequent study failed to reproduce its proliferative 
effect on lymphoid cells and the paper was retracted by the authors in 2003 26, 27. Nevertheless, 
independent studies revealed that c19orf10 was indeed produced by synoviocytes, macrophages, 
and adipocytes, although the function of c19orf10 remained elusive 28, 29. In this study, we identified 
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that c19orf10 was overexpressed in AFP-positive HCC samples. Our data imply that c19orf10 could 
activate the mitogen-activated protein kinase (MAPK)/Akt pathway and enhance cell proliferation 
in HCC cell lines, suggesting that c19orf10 may be a growth factor produced by tumor epithelial 
cells and/or stromal cells, and, therefore, would be a good target for the treatment of HCC.  
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Material and Methods  
SAGE and HCC samples 
HCC and normal liver SAGE libraries that we had constructed were re-analyzed using SAGE 2000 
software. The size of each SAGE library was normalized to 300,000 transcripts per library. Monte 
Carlo simulation was used to select genes whose expression levels were significantly different 
between the two libraries. Each SAGE tag was annotated using the gene-mapping website SAGE 
Genie database (http://cgap.nci.nih.gov/SAGE/) and the SOURCE database 
(http://smd.stanford.edu/cgi-bin/source/sourceSearch) as previously described 30. An additional 15 
SAGE libraries of normal and cancerous tissues from various organs were retrieved using the 
National Center for Biotechnology Information (NCBI) SAGEmap 
(http://www.ncbi.nlm.nih.gov/SAGE/). 
Fifteen HCC tissues (4 HBV-related and 11 HCV-related) and the corresponding 
non-cancerous liver tissues were obtained from HCC patients who received hepatectomy. Four 
normal liver tissues were obtained from patients undergoing surgical resection of the liver for the 
treatment of metastatic colon cancer. Additionally, 36 HCC tissues (17 HBV-related and 19 
HCV-related) were obtained from HCC patients undergoing hepatectomy. These samples were 
snap-frozen in liquid nitrogen immediately after resection and used for quantitative real-time 
detection PCR (RTD-PCR). Total RNA was extracted using a ToTALLY RNATM kit (Ambion, 
Austin,TX). 
The study protocol conformed to the ethical guidelines of the Declaration of Helsinki 
(1975) and was approved by the institutional ethical review board committee. All patients provided 
written informed consent for the analysis of the specimens. 
 
Laser Capture Microdissection (LCM) and RNA isolation 
LCM was performed as previously described 31. Briefly, 20 HCV-related surgically resected HCC 
tissues were frozen in OCT compound (Sakura Finetech, Torrance, CA) 32. Inflammatory cells and 
cancerous cells in HCC tissues were separately excised by LCM using a Laser Scissors CRI-337 
(Cell Robotics, Inc. Albuquerque, NM) under a microscope. Total RNA was isolated from these 
cells using a microRNA isolation kit (Stratagene, La Jolla, CA) in accordance with the supplied 
protocol, with slight modifications 31. 
 
Construction of C19ORF10 Expression Plasmid and Recombinant Adenovirus Vector 
PCR was performed on a Marathon cDNA library from Huh7 cells using the following primers: 
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sense primers; 5′-GACCCTAGTCCAACATGGCGGCGCCC-3′ (the first PCR), 
5′-ATGGCGGCGCCCAGCGGAGGGTGGAACGGC-3′ (the nested 2nd PCR), and anti-sense 
primers; 5′-CACCGGAGATGAGAAGGTGCCACCCGC-3′ (the first PCR), 
5′-CAGGGCTGCTGGTCACAGCTCAGTGCGCG-3′ (the nested 2nd PCR). The 5′ and 3′ends of 
the cDNA were isolated using a SMART RACE cDNA Ampl i f ica t ion  k i t  (Clontech, Mountain 
View, CA) according to the manufacturer’s recommendations. The PCR products were cloned into a 
TA vector (Invitrogen, Carlsbad, CA) to generate the pcDNA3.1- c19orf10 expression plasmid. 
Using this plasmid, a C-terminally FLAG-tagged construct of c19orf10 was generated and inserted 
in a pSI mammalian expression vector (Promega, Madison, WI), which was driven by the SV40 
promoter (pSI- c19orf10).  
The replication-incompetent recombinant adenovirus vector expressing FLAG-tagged 
c19orf10 (Ad. c19orf10-FLAG) was generated by homologous recombination using the AdMax 
system (Microbix, Toronto, Canada) as previously described 33. The generated recombinant 
adenovirus was purified by limiting dilution and the titer of viral aliquots was determined by the 
50% tissue culture infectious dose (TCID) method as previously described 34.  
 
RTD-PCR 
RTD-PCR was performed as previously described 31. Briefly, template cDNA was synthesized from 
1 μg of total RNA using SuperScript™ II RT (Invitrogen). RTD-PCR of c19orf10 (Hs. 
00384077_m1), AFP (Hs00173490_m1), GPC3 (Hs01018938_m1), KRT19 (Hs00761767_s1), and 
the ACTB internal control (Hs99999903_m1) was performed using a TaqMan® Gene Expression 
Assay kit (Applied Biosystems, Foster City, CA). The expression of selected genes was measured in 
triplicate by CT method using the 7900 Sequence Detection System (Applied Biosystems). 
 
Cell Lines and Transfection of Plasmids 
Human liver cancer cell lines HuH1, Huh7, Hep3B, HLE, and HLF, as well as HEK293 and 
NIH3T3 were cultured in Dulbecco’s modified eagle medium (Invitrogen) supplemented with 10% 
heat-inactivated fetal bovine serum (Invitrogen) in 5% CO2 at 37°C. Transfection of plasmids was 
performed using FuGENETM 6 (Roche Diagnostics, Indianapolis, IN) according to the 
manufacturer’s instruction. Briefly, 5 × 105 cells were seeded in a six-well plate 12 hours before 
transfection, and 3 g of plasmid DNA was used for each transfection. All experiments were 
repeated at least twice. 
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Purification of c19orf10-FLAG Fused Protein and Production of Anti-c19orf10 Antibody 
Approximately 500 ml of culture supernatant obtained from HEK293 cells infected with 
Ad.C19ORF10-FLAG at a multiplicity of infection of 20 was applied to an anti-FLAG affinity gel 
column (Sigma-Aldrich, St. Louis, MO). The column was subjected to elution by competition with 
FLAG peptide (5 μg/ml), and each 1 ml fraction of the eluted aliquot was collected to obtain the 
most concentrated c19orf10-FLAG protein in accordance with the manufacturer’s protocol. The 
anti-c19orf10 antibodies were developed by immunizing rabbits with repeated intradermal 
injections of oligo-peptides of c19orf10 (155-VAKAARSEL-163). Protein concentration was 
measured by the Bradford method. 
 
Silencing Gene Expression by Short Interfering RNA (siRNA)  
The selected siRNA targeting C19ORF10 (Si-C19ORF10; Silencer Select siRNAs s31855) and the 
irrelevant control sequence (Si-Control; Silencer Select siRNAs 4390843) were obtained from 
Applied Biosystems. Transfection of these siRNAs was performed using FuGENETM 6 (Roche 
Diagnostics) as previously described 30. Breifly, 2 × 105 cells were seeded in a six-well plate 12 
hours before transfection. A total of 100 pmol/L of siRNA duplex was used for each transfection. 
The experiments were performed at least twice. 
 
Cell Proliferation Assay  
Cell proliferation was evaluated in quadruplicate using a Cell Titer 96 MTS Assay kit (Promega). 
After incubation with MTS/PMS solution at 37°C for 2 h, the absorbance at 450 nm was measured. 
The experiments were performed at least twice. 
 
Cell Cycle Analysis 
Cells were fixed using 80% ice-cold ethanol and incubated with propidium iodide (PI) for 10 min. 
DNA content was analyzed using a FACS Caliber flow cytometer (BD Biosciences, San Jose, CA) 
counting 10,000 stained cells. The distribution of cells in each cell-cycle phase was determined 
using FlowJo software (Tree Star Inc., Ashland, OR). 
 
Western Blotting  
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer, and the extracts were 
subsequently electrophoresed on sodium dodecyl sulfate (SDS)-10% polyacrylamide gels and 
transferred onto protean nitrocellulose membranes. The blots were then incubated for 1 h with an 
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appropriate primary monoclonal antibody: phospho-PI3K (#4228), phospho-Akt (#4060), 
phospho-GSK-3β (#9323), phospho-c-Raf (#9427), phospho-MEK1/2 (#9154), phospho-p44/42 
MAPK (Erk1/2) (#4370), Cdk4 (CDK4 (#2906), Cdk6 (#3136), cyclinD1 (#2926), cyclinD3 
(#2936) , phospho-Rb (#9308), phospho-P53 (# 9286), phospho-cdc2 (#9111), and β-actin (#4970) 
(Cell Signaling Technology, Allschwil, Switzerland) and anti-FLAG antibodies (Sigma-Aldrich, St. 
Louis, MO). The blots were washed and exposed to peroxidase-conjugated secondary antibodies, 
such as anti-mouse or rabbit IgG antibodies, and visualized using the ECLTM kit (Amersham 
Biosciences Corp., Piscataway, NJ). All experiments were performed at least twice. 
 
Statistical Analyses 
Unpaired t-tests and Kruskal-Wallis tests were performed on the RTD-PCR and cell proliferation 
data using GraphPad Prism software (www.graphpad.com).  
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Results 
Identification of C19ORF10 overexpression in HCC by SAGE 
To comprehensively explore the candidate novel genes activated in HCC, we re-analyzed two 
SAGE libraries derived from HCC tissues and normal liver tissues 30. After normalization of each 
SAGE library size to 300,000 tags, we compared the HCC and normal liver libraries to obtain the 
list of genes overexpressed in HCC. We identified 79 genes significantly overexpressed in the HCC 
library by more than 10-fold when compared with the normal liver library (Supplemental Table 1). 
Among them, we explored expressed sequence tags (ESTs) as candidates for novel HCC-related 
genes to identify 8 unique tags corresponding to 7 ESTs (Table 1). We especially focused on the 
EST chromosome 19 open reading frame 10 (c19orf10) because the sequence presumably encoded 
a secretory protein with a signal peptide sequence (Fig. 1A).  
When we examined the expression profiles of c19orf10 using retrieved SAGE data from 
various cancers and their normal counterparts, we identified that c19orf10 was abundantly 
expressed in human HCC (Fig. 1B). We further examined the publicly available EST profiles of 
c19orf10 (http://www.ncbi.nlm.nih.gov/unigene), and confirmed its tendency to be overexpressed in 
HCC compared with the normal liver (data not shown). We validated the overexpression of 
c19orf10 in 15 independent HCC tissues and adjacent non-cancerous liver tissues by RTD-PCR. 
Gene expression of c19orf10 was significantly higher in the HCC tissues than in the normal liver 
tissues and adjacent non-cancerous liver tissues (P = 0.014 and 0.048, respectively; Fig. 1C). 
C19orf10 expression was elevated in HCC tissues compared with the adjacent non-cancerous liver 
tissues in 10 of 15 patients (66.7%; Fig. 1D). 
 
Overexpression of C19ORF10 in AFP-positive HCC 
As HCC is a heterogeneous mixture of cancer epithelial cells and stromal cells, and a previous 
report indicated that c19orf10 is expressed in fibroblast-like synoviocytes. We therefore evaluated 
the expression of c19orf10 in tumor epithelial cells and stromal cells separately using LCM and 
RTD-PCR in 20 HCC tissues (Fig. 2A). Although tumor stromal cells expressed c19orf10 at some 
level, the expression levels were significantly higher in tumor epithelial cells than in stromal cells 
(P = 0.006) (Fig. 2B). 
To explore the relationship of c19orf10 with other established HCC markers, we 
investigated the gene expression of c19orf10, AFP (alpha-fetoprotein), KRT19 (cytokeratin 19), and 
GPC3 (glypican 3). Because only one of15 HCC tissues analyzed above (Fig. 1D) was 
AFP-positive (data not shown), we further investigated the expression of c19orf10 in an additional 
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36 HCC tissues using RTD-PCR. Interestingly, c19orf10 expression was significantly positively 
correlated with AFP (r = 0.44, P = 0.008), but not with KRT19 (r = 0.08, P = 0.66) nor GPC3 (r = 
0.11, P = 0.54) (Figs. 2C–E). Furthermore, when we examined the expression of c19orf10 in 
AFP-positive (HuH1, HuH7, and Hep3B) and –negative (HLE and HLF) HCC cell lines, we 
identified the overexpression of c19orf10 in AFP-positive HCC cell lines (Fig. 2F). These data 
suggested that c19orf10 is overexpressed and may play some role in AFP-positive HCCs.  
 
C19orf10 regulates MAPK/Akt pathways and activates cell proliferation 
To explore the functional role of c19orf10 in HCC, we performed c19orf10 overexpression and 
knockdown studies using c19orf10-low HLE cells, and c19orf10-high Hep3B and HuH7 cells, 
respectively. When we transfected HLE cells with pcDNA3.1 or pcDNA3.1- c19orf10 plasmids, we 
identified an approximately 6-fold overexpression of c19orf10 when compared with the control 48 
hours after transfection ( P < 0.0001) (Fig. 3A). Interestingly, cell proliferation was modestly, but 
significantly, enhanced compared with the control 72 hours after transfection (P = 0.0015) (Fig. 
3B).  
We also transfected siRNAs targeting an irrelevant sequence (Si-Control) or c19orf10 (Si- 
c19orf10) in Hep3B and HuH7 cells. We observed an approximately 50% decrease in c19orf10 
expression in Hep3B cells transfected with Si- c19orf10 compared with the control 48 hours after 
transfection with statistical significance (P < 0.0001). In this condition, cell proliferation was 
suppressed to 50% compared with the control 72 hours after transfection (P < 0.0001) (Figs. 3C, D). 
When we performed cell cycle analysis of HuH7 cells transfected with Si-Control or Si- c19orf10, 
we identified an increase of G1-phase cells and a decrease of S- and G2-phase cells by c19orf10 
knockdown, suggesting the G1 cycle arrest was caused by the knockdown of c19orf10 (Fig. 3E).  
We examined the representative MAPK/Akt pathway-associated proteins and cell cycle 
regulators using Western blotting 72 hours after siRNAs transfection (Fig. 3F). Interestingly, 
phosphorylation of c-Raf, MEK, MAPK, PI3K, and pAkt was inhibited by knockdown of c19orf10, 
suggesting the involvement of c19orf10 in the MAPK/Akt pathways. Furthermore, phosphorylation 
of Rb, CDK4, and CDK6 was also inhibited by knockdown of c19orf10, consistent with the 
observation of G1 cell cycle arrest by C19ORF10 knockdown. PTEN, p53, and phosphorylated 
CDC2 protein expression was not affected by knockdown of c19orf10.  
  
C19orf10 encodes the secretory protein and stimulates cell proliferation  
As the sequence of c19orf10 suggested that it encodes a secretory protein, we transfected pSI- 
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c19orf10-FLAG in NIH3T3 cells and examined the culture supernatant. Immunoprecipitation of the 
collected culture supernatant 48 h after transfection using anti-FLAG antibodies indicated the 
existence of a 17-kDa protein (c19orf10), compatible with the molecular weight of the 142 amino 
acids protein encoded by c19orf10 (Fig. 4A). We purified c19orf10-FLAG protein from the 
supernatant of HEK293 cells infected with Ad. c19orf10-FLAG using an anti-FLAG column. 
Supplementation of purified c19orf10-FLAG into the culture media for 72 h enhanced the 
proliferation of HLE cells in a dose dependent manner with statistical significance, whereas control 
FLAG peptides and BSA had no effects on cell proliferation (Fig. 4B). Western blot analysis of 
HLE cells cultured with purified c19orf10-FLAG (40 ng/ml) or BSA control (40 ng/ml) indicated 
the immediate strong phospholyration of Akt peaked 5 minutes after supplementation (Fig. 4C). The 
modest phospholyration of GSK3 (Ser9) and p44/42 MAPK also followed and peaked 60 minutes 
after c19orf10 supplementation. These data suggest that Akt pathway might be directly involved in 
the c19orf10-mediated cell proliferation signaling with the subsequent activation of MAPK pathway. 
Furthermore, addition of antibodies against c19orf10 peptides to the culture media abolished the 
cell proliferation induced by c19orf10, whereas control IgG had no effects (Fig. 4D). Taken together, 
these data suggest that c19orf10 may be a growth factor overexpressed in AFP-positive HCCs and 
activates the Akt/MAPK pathways, potentially through the activation of an unidentified c19orf10 
receptor.  
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Discussion 
SAGE facilitates the measurement of transcripts from normal and malignant tissues in a non-biased 
and highly accurate, quantitative manner. Indeed, SAGE produces a comprehensive gene expression 
profile without a priori gene sequence information, leading to the identification of novel transcripts 
potentially involved in the pathogenesis of human cancer 19. In this study, we identified seven 
SAGE tags potentially corresponding to novel genes activated in HCC. Among them, we identified 
the secretory protein c19orf10 activated in a subset of HCCs. 
Several serum markers including AFP, DCP, and Glypican 3 are currently used for the 
detection and/or the evaluation of the treatment for HCCs in the clinic 15-18, 35. These markers are 
known as oncofetal proteins, that is, expressed in the fetus, transcriptionally suppressed in the adult 
organ, and reactivated in the tumor. We identified that the expression of c19orf10 positively 
correlated with AFP expression, but did not correlate with the expression of GPC3 or the biliary 
marker KRT19. As c19orf10 was rarely detected in the normal liver, it is possible that c19orf10 is 
also an oncofetal protein activated in HCC. We are currently developing a system to detect serum 
c19orf10 in HCC patients, and the significance of the serum c19orf10 value as an HCC marker 
should be clarified.  
Recent advancement in molecular biology has revealed the considerable diversity of 
transcription initiation and/or termination of genes altered in the process of carcinogenesis. Indeed, 
using 5’ SAGE approach, we recently discovered the novel intronic transcripts activated in HCC 36. 
Interestingly, when we investigated the transcription initiation of c19orf10 using the 5’ SAGE 
database, we identified a potential 5’ splice variant initiated from the second exon of c19orf10 (data 
not shown). Although we have not yet validated the presence of 5’ splice variants in c19orf10 by 
PCR, examination of 5’ EST database also suggested the presence of the similar splice variants 
(GenBank Accession Number CR980295, BQ680744, BQ648461, etc). Alteration of transcription 
initiation/termination in c19orf10 might affect the abundance or function of c19orf10 protein, and 
the details of 5’ splice variants in c19orf10 should be clarified in future studies. 
Molecular targeting therapy has rapidly emerged for solid tumors as well as for leukemia 
37-39. Sorafenib is a multi-kinase inhibitor targeting Raf kinase in the MAPK pathway as well as 
VEGFR and the platelet-derived growth factor-receptor 40, 41. In this study, we identified that 
c19orf10 activates the MAPK and Akt/PI3K pathways, and contributes to the proliferation of HCC 
cell lines, although we still could not discover the potential receptor of c19orf10. Development of a 
neutralizing c19orf10 antibody may provide novel therapeutic options for HCC patients to inhibit 
these signaling pathways, and its efficacy should be evaluated in the future. 
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 Recently, c19orf10 was found to be expressed in fibroblast-like synoviocytes in the 
synovium using a proteomics approach 29. In addition, a recent paper indicated that c19orf10 was 
expressed in pre-adipocyte cells and involved in adipogenesis using two-dimensional 
electrophoresis mass spectrometry analysis 28. Thus, c19orf10 may have pleiotropic effects on 
various lineages of normal organs in various developmental stages, and the clarification of its 
distribution and biological properties in the whole body may provide more detailed information 
about the function of c19orf10.   
In conclusion, we have identified the protein c19orf10 that regulates the Akt /MAPK 
pathways and cell cycle through an unidentified mechanism in HCC. Although further studies 
should be conducted to detect the potential c19orf10 receptor or signaling molecules binding to 
c19orf10, the current study suggests that c19orf10 may be a novel growth factor, a potential tumor 
marker, and also a potential target molecule for HCC treatment. 
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A. Structure of a c19orf10 gene and a c19orf10 protein. The DNA sequence of c19orf10 and amino 
acid alignment of the encoded c19orf10 protein are shown. C19orf10 is predicted to have a 
molecular weight of 17 kDa and contain a signal peptide cleavage site (indicated as a black arrow). 
B. C19orf10 gene expression profiles in various tissues by SAGE. Y axis indicates the number of 
tags corresponding to c19orf10 in each tissue. C & D. RTD-PCR analysis of c19orf10. RNA was 
isolated from 34 tissue samples: 15 HCC, 15 corresponding non-cancerous liver samples, and 4 
normal liver samples. Differential expression of each gene among normal liver tissues, 
non-cancerous liver tissues, and HCC tissues was examined using the Kruskal-Wallis test and 
unpaired t-test. The mean value of gene expression data in each group is indicated (C). C19orf10 




A. Representative photomicrographs of an HCC tissue used for LCM (toluidine blue staining). 
Inflammatory mononuclear cells and stromal cells were separately captured (Left: Pre-LCM, right: 
Post-LCM). B. RTD-PCR analysis of c19orf10 expression in inflammatory mononuclear cells and 
tumor epithelial cells in 20 HCV-related HCC tissues. Tumor-inflammatory mononuclear cells and 
stromal cells were isolated using LCM. RNAs were isolated from these cells as well as parenchymal 
tissues from the same liver, followed by RTD-PCR for c19orf10 gene expression. Expression of the 
c19orf10 gene was higher than that observed in HCC-infiltrating inflammatory mononuclear cells. 
*,P < 0.05. C–E. Scatter plot analysis of c19orf10, AFP, KRT19, and GPC3 expression in HCC. 
RNA was isolated from 17 HBV-related HCC and 19 HCV-related HCC. F. RTD-PCR analysis of 




A. RTD-PCR analysis of c19orf10 expression in HLE cells transfected with pcDNA3.1 or 
pcDNA3.1-c19orf10 plasmids. B. Cell proliferation assay of HLE cells transfected with pcDNA3.1 
or pcDNA3.1-c19orf10 plasmids. Cell proliferation was evaluated 72 h after each plasmid 
transfection. C. RTD-PCR analysis of c19orf10 expression in Hep3B cells transfected with 
Si-Control or Si-c19orf10. Gene expression was measured in triplicates 48 h after transfection. D. 
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Cell proliferation assay of Hep3B cells transfected with Si-Control or Si-c19orf10. Cell 
proliferation was evaluated 72 h after siRNA transfection. E. Cell cycle analysis of HuH7 cells 
transfected with Si-Control or Si-c19orf10. Cell cycle was evaluated 72 h after siRNA transfection. 
A black arrow indicates the G2 phase peak. F. Western blotting analysis of Huh7 cells transfected 
with Si-Control or Si-c19orf10. Cells were lysed by RIPA buffer 72 h after siRNA transfection. 
 
Fig. 4. 
A. Coomassie blue staining and Western blotting of culture supernatant of NIH3T3 cells transfected 
with pSI-c19orf10-FLAG. A black arrow indicates the 17-kDa c19orf10 protein. B. Cell 
proliferation assay of HLE cells supplemented with recombinant c19orf10-FLAG. Cell proliferation 
was measured in quadruplicates 72 h after supplementation. C. Western blotting of HLE cells 
supplemented with c19orf10-FLAG (40 ng/ml). Cells were lysed at indicated time after c19orf10 
supplementation. D. Cell proliferation assay of HLE cells supplemented with control BSA (40 
ng/ml) (white bar), c19orf10-FLAG (40 ng/ml) (light grey bar), c19orf10-FLAG (40 ng/ml) 





Table 1. ESTs overexpressed in the HCC library
Tag Sequence P-value HCC normal liver T/N ratio Name UniGene ID
TGGGCAGGTG <0.00001 33 0 >33 Chromosome 5 open reading frame 13 Hs.483067
GCAAAATATC <0.00001 31 2 15.5 Liver cancer associated non coding mRNA, partial sequen Hs.214343
AGCCTGCAGA 0.0002 12 1 12 Chromosome 19 open reading frame 10 Hs.465645
TTGTGCACGT 0.000228 12 1 12 CDNA FLJ45284 fis, clone BRHIP3001964 Hs.514273
ACATTCTTGT 0.000042 12 0 >12 Transcribed locus, strongly similar to XP_496055.1 Hs.76704
ACAAGTACCC 0.001161 10 1 >10 Chromosome 5 open reading frame 13 Hs.483067
GAGGTGAAGG 0.000174 10 0 >10 KIAA1914 Hs.501106
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P = 0.014 
P = 0.048
  1 GCGGCCGTGACTGAATTCTAGCAAGATGGCAGCCCCCAGCGGAGGCTTCTGGACTGCGGT 
 MetAlaAlaProSerGlyGlyPheTrpThrAlaVal 
  61 GGTCCTGGCGGCCGCAGCGCTGAAATTGGCCGCCGCTGTGTCCGAGCCCACCACCGTGCC
13 ValLeuAlaAlaAlaAlaLeuLysLeuAlaAlaAlaValSerGluProThrThrValPro  
  121 ATTTGACGTGAGGCCCGGAGGGGTCGTGCATTCGTTCTCCCAGGACGTAGGACCCGGGAA
33 PhrAspValArgProGlyGlyValValHisSerPheSerGlnAspValGlyProGlyAsn  
  181 CAAGTTTACATGTACATTCACCTACGCTTCCCAAGGAGGGACCAACGAGCAATGGCAGAT
53 LysPheThrCysThrPheThrTyrAlaSerGlnGlyGlyThrAsnGlnGlnTrpGlnMet  
  241 GAGCCTGGGGACAAGTGAAGACAGCCAGCACTTTACCTGTACCATCTGGAGGCCCCAGGG
73 SerLeuGlyThrSerGluAspSerGlnHisPheThrCysThrIleTrpArgRpoGlnGly  
 301 GAAATCCTACCTCTACTTCACACAGTTCAAGGCTGAGTTGCGAGGTGCTGAGATCGAGTA
93 LysSerTyrLeuTyrPheThrGlnPheLysAlaGluLeuArgGlyAlaGluIleGluTyr  
  361 TGCCATGGCCTACTCCAAAGCCGCATTTGAGAGAGAGAGTGATGTCCCCCTGAAAAGTGA
113 AlaMetAlaTyrSerLysAlaAlaPheGluArgGluSerAspValProLeuLysSerGlu  
  421 GGAGTTTGAAGTGACCAAGACAGCAGTGTCTCACAGGCCTGGGGCCTTCAAAGCTGAGCT
133 GluPheGluValThrLysThrAlaValSerHisArgProGlyAlaPheLysAlaGluLeu  
































































































































































P = 0.0015P < 0.0001
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Supplemental Table 1 Genes overexpressed in the HCC library compared with the normal liver library
Tag Sequence P-value HCC normal liver T/N ratio Name UniGene ID
CCAAGACTTC<0.00001 449 3 149.6667 no reliable match
CTAAGGTAGT<0.00001 61 0 >61 no reliable match
TGGGCAGGTG<0.00001 33 0 >33 Chromosome 5 open reading frame 13 Hs.483067
CTGACTTGTG<0.00001 24 0 >24 Major histocompatibility complex, class I, B Hs.77961
CTGCCCTCCC <0.00001 24 1 24 Iduronidase, alpha-L- Hs.89560
TACAGTATGT<0.00001 207 9 23 Glutamate-ammonia ligase (glutamine synthase) Hs.518525
GCAAAAGAAA<0.00001 23 1 23 Glutamate-ammonia ligase (glutamine synthase) Hs.518525
GATTTCTTTG <0.00001 21 0 >21 glypican 3 Hs.435036
TGATATAAAT<0.00001 21 0 >21 Cytochrome P450, family 3, subfamily A, polypeptide 4 Hs.442527
TCCCCGCTAC<0.00001 21 0 >21 no reliable match
TAAAAAAGGT<0.00001 19 1 19 multiple match
GCAAAATATC<0.00001 31 2 15.5 Liver cancer associated non coding mRNA, partial sequence Hs.214343
GATCACTGCT<0.00001 30 2 15 multiple match
CTTCAGAGAA<0.00001 15 1 15 Oxoglutarate dehydrogenase-like Hs.17860
GGGTTTTTAT <0.00001 15 1 15 multiple match
GCTTATGTTA <0.00001 15 0 >15 multiple match
CTATACTTTG <0.00001 14 1 14 Aldehyde dehydrogenase 5 family, member A1 Hs.371723
TGCTACTGGT<0.00001 14 1 14 Surfeit 1 Hs.512464
GGCCCAGGAC<0.00001 14 0 >14 multiple match
GCTGCGGTCC<0.00001 14 1 14 multiple match
GATCTCCTGC<0.00001 14 1 14 multiple match
ATGCTCCCTG<0.00001 14 0 >14 multiple match
TTACTTATAC <0.00001 14 0 >14 multiple match
TCTTCAACAA<0.00001 14 0 >14 multiple match
CCAGGGGAGA<0.00001 38 3 12.66667 interferon, alpha inducible protein 27 Hs.532634
TCACTTTCAT <0.00001 12 1 12 Dehydrogenase E1 and transketolase domain containing 1 Hs.104980
AGAGCGCAGC<0.00001 12 1 12 crystallin, alpha A Hs.184085
CCCGGCTCTT <0.00001 12 0 >12 Platelet-activating factor acetylhydrolase, isoform Ib, beta subunit 30kDa Hs.188501
AAGCTAAGTC<0.00001 12 1 12 transmembrane protein 7 Hs.196584
GTGATGAGCT<0.00001 12 1 12 carboxylesterase 2 (intestine, liver) Hs.282975
GTGCACTGTG<0.00001 12 0 >12 Testis enhanced gene transcript (BAX inhibitor 1) Hs.35052
AGCCTGCAGA<0.00001 12 1 12 Chromosome 19 open reading frame 10 Hs.465645
GAGCTCCACA<0.00001 12 1 12 Protein kinase (cAMP-dependent, catalytic) inhibitor gamma Hs.472831
CTGTTATAGG<0.00001 12 0 >12 YME1 like 1 (S. cerevisiae) Hs.499145
TTGTGCACGT<0.00001 12 1 12 CDNA FLJ45284 fis, clone BRHIP3001964 Hs.514273
CAGCTCCGCT<0.00001 12 0 >12 DUTP pyrophosphatase Hs.527980
TTTTTAATGT <0.00001 12 1 12 H3 histone, family 3A Hs.533624
GCGTCGGGGA<0.00001 12 1 12 interferon (alpha, beta and omega) receptor 2 Hs.549042
ACATTCTTGT <0.00001 12 1 12 Transcribed locus, strongly similar to XP_496055.1 similar to Hs.76704
CTGCTGTAAT<0.00001 12 0 >12 multiple match
TTATCAAAAA<0.00001 12 1 12 multiple match
TATCACTCTG <0.00001 12 0 >12 multiple match
GTAGGTTGTC<0.00001 12 1 12 multiple match
TGTGGTGGTG<0.00001 12 1 12 multiple match
CCAGCTGCCA<0.00001 12 1 12 multiple match
TAAATACAGT<0.00001 12 0 >12 multiple match
CTGTGTCTGT <0.00001 12 1 12 multiple match
TGATGGCGCA<0.00001 12 0 >12 no reliable match
CACCTAATTA<0.00001 12 1 12 no reliable match
TCCACTATTA <0.00001 12 0 >12 no reliable match
CTAAATCTCG<0.00001 12 0 >12 no reliable match
TGGTGTATGC<0.00001 35 3 11.66667 Tag matches mitochondrial sequence
TCCTCTCTGT <0.00001 23 2 11.5 Solute carrier family 38, member 3 Hs.76460
TTAACCCTCT 0.00016 10 0 >10 H3 histone, family 3B (H3.3B) Hs.180877
ATGACTTAGG 0.00113 10 1 10 UDP glycosyltransferase 2 family, polypeptide B10 Hs.201634
TGACTACTGA 0.00109 10 1 10 apolipoprotein L, 6 Hs.257352
TTAGGCCCTC 0.00111 10 1 10 Erythrocyte membrane protein band 4.1 like 4B Hs.269180
TTATTATCAC 0.00112 10 1 10 factor H related protein 5 Hs.282594
CCTGTCCAGC 0.00105 10 1 10 BCL2 like 1 Hs.305890
AGAACTTCCT 0.00102 10 1 10 defensin, beta 1 Hs.32949
GCCAAGTTTG 0.00017 10 0 >10 proteasome (prosome, macropain) 26S subunit, non ATPase, 1 Hs.3887
TAATTACTCT 0.00016 10 0 >10 13kDa differentiation associated protein Hs.44163
ATTTCTTGCC 0.00103 10 1 10 Mitochondrial ribosomal protein L38 Hs.442609
ACACAGTTTT 0.00014 10 0 >10 FAT tumor suppressor homolog 1 (Drosophila) Hs.481371
ACAAGTACCC 0.00108 10 1 10 Chromosome 5 open reading frame 13 Hs.483067
TGGAGAGCAA 0.00107 10 1 10 S-adenosylhomocysteine hydrolase-like 1 Hs.485365
GAGGTGAAGG 0.00015 10 0 >10 KIAA1914 Hs.501106
GCTGGAGGAG 0.00016 10 0 >10 Transcribed locus Hs.520115
ACCAGCAAAT 0.00017 10 0 >10 phosphoinositide 3 kinase, regulatory subunit, polypeptide 1 (p85 alpha) Hs.6241
CTGCCCGCCT 0.00014 10 0 >10 multiple match
GCTTGAATAA 0.00015 10 0 >10 multiple match
GTAAGATTTG 0.0011 10 1 10 multiple match
CCCGCCCCCG 0.00106 10 1 10 multiple match
CAAGGATCTA 0.00014 10 0 >10 multiple match
GAAACTGAAG 0.00014 10 0 >10 multiple match
CAGACTATGT 0.00115 10 1 10 multiple match
ATTACACCAC 0.00015 10 0 >10 multiple match
AACAGAAGCA 0.0011 10 1 10 multiple match
GAAATCCAAA 0.00013 10 0 >10 multiple match
